Penile cancer

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
수요일, 1월 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

Retrieved on: 
일요일, 6월 5, 2022
Immunotherapy, Penile cancer, Head, HNSCC, Cell, Society, Lung, RECIST, HPV16, Food, Progression-free survival, Vulvar cancer, Standard of care, Human papillomavirus infection, Degenerative disease, Cancer, ASCO, Annual general meeting, Prostate cancer, CD8, Pembrolizumab, American Society of Clinical Oncology, Prostate, Therapy, GLOBE, Patient, Fast track (FDA), HBV, Technology, Arenavirus, E7, DNA, HPV, NASDAQ, NEW, Clinical trial, Population, HIV, Neck, Gilead, Protein, KRAS, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD Anderson Cancer Center, Person, Safety, Lymphocytic choriomeningitis, Vaccine, Pharmaceutical industry

The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • These results help focus our efforts as we move HB-202/HB-201 at the recommended Phase 2 dose into the Phase 2 portion of the trial.
  • Sixty-eight patients with advanced HPV16+ cancers were treated in the Phase 1 trial as of March 31, 2022.
  • Fifty-four patients had advanced HPV16+ head and neck cancers with a median of three prior therapies (range of 1-11), including a checkpoint inhibitor regimen in 50 of the 54.

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Retrieved on: 
목요일, 5월 26, 2022
Cancer, DNA, Degenerative disease, Immunotherapy, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBV, Food, Vulvar cancer, NEW, KRAS, Progression-free survival, HPV16, Patient, Science, Prostate, Gilead, NASDAQ, PD-1, RECIST, Fast track (FDA), CD8, Clinical trial, Society, Penile cancer, American Society of Clinical Oncology, Cell, HNSCC, Pembrolizumab, Arenavirus, Prostate cancer, Neck, Technology, Safety, Biomarker, ASCO, Standard of care, Lymphocytic choriomeningitis, Head, Lung, Human papillomavirus infection, Protein, HIV, E7, HPV, GLOBE, Medical imaging, Pharmaceutical industry, Online shopping, Vaccine

We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.

Key Points: 
  • We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.
  • The final analysis shows that HB-201 and 2-vector HB-202/HB-201 were generally well tolerated and showed anti-tumor activity in these difficult-to-treat patients.
  • The primary endpoint of Phase 1 is a recommended Phase 2 dose.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Wouche Away™ Prebiotic Total Body Cleanser by Glyciome, LLC Chosen as Finalist for 2021 Idaho Innovation Award's Consumer Product of the Year

Retrieved on: 
목요일, 9월 30, 2021
Transfer, Post Falls, Idaho, Stinger, Cancer, Irritation, Hygiene, Vertically transmitted infection, Parent, Infection, Urinary tract infection, Inflammation, Cervical cancer, Ectopic pregnancy, FDA, Sexual dysfunction, Infertility, Cosmetics, Penile cancer, Coeur d'Alene, Bacteria, Invention, The Good Life, University, Dry, Acne, LLC, Face, Woman, International, Disease, POST, Risk, Technology, Tissue, Seborrhoeic dermatitis, Incontinence, Vaginitis, Skin

Wouche Away is the first consumer product by Glyciome (a women-owned LLC).

Key Points: 
  • Wouche Away is the first consumer product by Glyciome (a women-owned LLC).
  • It was developed, and is manufactured, in Glyciome facilities at the University of Idaho Research Park (Post Falls, Idaho).
  • "We are ecstatic to be chosen as a finalist for the 2021 Idaho Consumer Product of the Year," said Glyciome Chief Executive Officer and Wouche Away co-inventor Dr. Joanna Ellington (glyciome.com).
  • Wouche Away can be purchased online at woucheaway.com or Amazon, and in regional Spokane and Coeur d'Alene retail locations.